← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Myers Scott Dunseth
Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001356256
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 0
- Purchases · 24M
- 2
- Average purchase
- $35.3K
- Median purchase
- $35.3K
- Gross purchase value
- $70.5K
Companies: DYNAVAX TECHNOLOGIES CORP | Zentalis Pharmaceuticals, Inc.
2 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2025-08-25 | DYNAVAX TECHNOLOGIES CORP | DVAX | Director | $41.1K | Open filing |
| 2025-04-30 | Zentalis Pharmaceuticals, Inc. | ZNTL | Director | $29.4K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 0/—
- Large purchase ≥ $100k
- 0/2
- Cluster buying · 15D
- 0/2
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.